Pfizer Inc. (PFE)
PFE's Colorectal Cancer Drug Meets Other Dual Primary Goal of PFS
Pfizer's late-stage BRAF V600E-mutant mCRC study of the Braftovi combo regimen meets its other dual primary endpoint of PFS with statistical significance.
Pfizer Beats Q4 Revenue, EPS Estimates
Pharmaceuticals giant Pfizer (PFE -0.21%) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. The company reported an adjusted earnings per share of $0.63, significantly above the analyst consensus of $0.47, while generating revenue of $17.76 billion, surpassing expectations of $17.35 billion.
Pfizer (PFE) Beats Q4 Earnings and Revenue Estimates
Pfizer (PFE) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.10 per share a year ago.
Mizuho's Jared Holz on Merck and Pfizer Q4 results, 2025 outlook for Big Pharma stocks
Jared Holz, Mizuho Securities America healthcare sector strategist, joins 'Squawk Box' to break down the quarterly earnings results of Merck and Pfizer, 2025 outlook for pharmaceutical stocks, and more.
Pfizer stock climbs on Q4 revenue and earnings beat, reaffirmed guidance
“We remain confident in our ability to return to pre-pandemic operating margins in the coming years,” said Pfizer CFO David Denton.
Pfizer tops earnings estimates as Covid product sales beat expectations and cost cuts pay off
Pfizer reported fourth-quarter earnings and revenue that beat estimates as sales of the company's Covid products came in higher than expected and cancer drugs from Seagen boosted revenue. The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its Covid business and stock price over the last two years.
Pfizer beats fourth-quarter profit estimates on cost-cutting efforts
U.S. drugmaker Pfizer beat Wall Street estimates for fourth-quarter profit on Tuesday, helped by cost-cutting efforts and better-than-expected sales of its COVID vaccine.
Pfizer Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Pfizer Inc. PFE will release its fourth-quarter financial results, before the opening bell, on Tuesday, Feb. 4, 2025.
Merck Vs. Pfizer: Which Pharmaceutical Giant Will Prevail In Q4 Earnings?
Merck & Co Inc MRK and Pfizer Inc PFE are duking it out for investor attention with fourth-quarter earnings being reported on Tuesday.
Will Non-COVID Drugs Drive PFE's Top Line in Q4 Earnings?
Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the fourth quarter.
Smaller US winter COVID wave adds pressure to Pfizer turnaround
Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could put additional pressure on Pfizer to find growth from its non-COVID treatments.
Pfizer resolves conservative challenge to diversity fellowship program
Pfizer has resolved a lawsuit by a conservative group that alleged that a fellowship program that the drugmaker established to boost the pipeline of Black, Latino and Native American people in leadership positions at the company unlawfully discriminated against white and Asian-American applicants.
